What is Leuko Labs?
Leuko Labs is an MIT spin-out dedicated to revolutionizing patient monitoring through its flagship device, PointCheck. The technology utilizes noninvasive, light-based imaging of superficial capillaries near the fingernail to assess white blood cell levels, a critical metric for cancer patients undergoing chemotherapy. By providing a reliable, at-home alternative to traditional blood draws, the company aims to mitigate infection risks and facilitate earlier clinical interventions. The firm maintains a robust research pipeline, collaborating with major institutions such as the Veterans Health Administration to validate its platform through rigorous clinical trials and peer-reviewed studies.
How much funding has Leuko Labs raised?
Leuko Labs has raised a total of $5M across 1 funding round:
Series A
$5M
Series A (2022): $5M with participation from IAG Capital Partners, Nina Capital, Good Growth Capital, and Hth
Key Investors in Leuko Labs
IAG Capital Partners
IAG Capital Partners is a venture capital firm that specializes in leading investment rounds from seed to Series C, providing financial support to innovative companies at various stages of their development.
Nina Capital
Nina Capital is a specialized venture capital firm focused on investing in health technology companies at the pre-seed and seed stages, aiming to transform healthcare through information technology.
Good Growth Capital
Good Growth Capital is an early-stage venture capital firm specializing in transformative science and technology investments, with a focus on life sciences and medical devices.
What's next for Leuko Labs?
With the recent influx of capital, Leuko Labs is poised to accelerate its clinical validation efforts and refine its AI-driven diagnostic algorithms. The strategic focus will likely shift toward securing regulatory milestones and expanding partnerships with cancer centers to integrate PointCheck into standard care protocols. As the company scales, it faces the dual challenge of maintaining high diagnostic accuracy while navigating the complex regulatory landscape of medical device commercialization. The backing from specialized health-tech investors suggests a clear path toward market entry and long-term sustainability in the digital health ecosystem.
See full Leuko Labs company page
